Biogen Receptin (CD4)
Biogen Receptin (CD4): AIDS drug is proceeding to Phase II efficacy study in conjunction with the National Institute for Allergy and Infectious Diseases, firm announces April 28. The new trials will test the safety and efficacy of Biogen's recombinant soluble CD4 in combination with Burroughs Wellcome's Retrovir (AZT). Biogen will present Phase I study results at the AIDS conference in Montreal in June.
You may also be interested in...
Court finds US FDA did not impede Catalyst orphan exclusivity for Firdapse as it approved different indication for competing product. Biogen loses 10-year patent battle against competing multiple sclerosis drug makers.
Cover Three Nutritional Brain Defense marketer agrees to pull claims suggesting the supplement beverage can protect against traumatic brain injury after a test the firm on DHA submitted as support contained considerably higher levels of the ingredient than included in the product.
The top-line data in the ultra-rare disease are also the first to demonstrate safety and efficacy of an RNAi therapy in patients six years and younger.